Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study.

[1]  J. Haller,et al.  Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. , 2014, Ophthalmology.

[2]  P. Mitchell,et al.  Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. , 2014, Ophthalmology.

[3]  Kang Zhang,et al.  Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). , 2013, Ophthalmology.

[4]  Usha Chakravarthy,et al.  Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial , 2013, The Lancet.

[5]  Q. Nguyen,et al.  Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. , 2013, Ophthalmology.

[6]  P. Rockwell,et al.  Signaling through the vascular endothelial growth factor receptor VEGFR-2 protects hippocampal neurons from mitochondrial dysfunction and oxidative stress. , 2013, Free radical biology & medicine.

[7]  Glenn J Jaffe,et al.  Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. , 2013, Ophthalmology.

[8]  Allen C Ho,et al.  Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2013, Ophthalmology.

[9]  P. Khaw,et al.  VEGF-A Is Necessary and Sufficient for Retinal Neuroprotection in Models of Experimental Glaucoma , 2013, The American journal of pathology.

[10]  E. Souied,et al.  MULTIMODAL EVALUATION OF FOVEAL SPARING IN PATIENTS WITH GEOGRAPHICATROPHY DUE TO AGE-RELATED MACULAR DEGENERATION , 2013, Retina.

[11]  P. Campochiaro,et al.  Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. , 2013, JAMA ophthalmology.

[12]  A. Ho,et al.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.

[13]  E. Souied,et al.  Choroidal neovascularisation complicating geographic atrophy in age-related macular degeneration , 2012, British Journal of Ophthalmology.

[14]  U. Schmidt-Erfurth,et al.  RETREATMENT WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY BASED ON CHANGES IN VISUAL ACUITY AFTER INITIAL STABILIZATION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 3-Year Follow-up Results , 2012, Retina.

[15]  Ursula Schmidt-Erfurth,et al.  One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. , 2012, Ophthalmology.

[16]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[17]  G. Ying,et al.  Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results: Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group‡* , 2012 .

[18]  W. Freeman,et al.  HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. , 2012, Ophthalmology.

[19]  P. Campochiaro,et al.  Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. , 2012, Ophthalmology.

[20]  P. Campochiaro,et al.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. , 2011, Ophthalmology.

[21]  U. Schmidt-Erfurth,et al.  Performance of OCT segmentation procedures to assess morphology and extension in geographic atrophy , 2011, Acta ophthalmologica.

[22]  Jennifer K. Sun,et al.  Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. , 2011, Ophthalmology.

[23]  P. Rosenfeld,et al.  Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. , 2011, Ophthalmology.

[24]  R. Klein,et al.  Prevalence of age-related macular degeneration in the US population. , 2011, Archives of ophthalmology.

[25]  P. Campochiaro,et al.  Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells , 2010, Journal of cellular physiology.

[26]  Magali Saint-Geniez,et al.  An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris , 2009, Proceedings of the National Academy of Sciences.

[27]  Frederick L Ferris,et al.  Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. , 2009, Archives of ophthalmology.

[28]  Kenneth P. Roos,et al.  Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.

[29]  David T. Shima,et al.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. , 2007, The American journal of pathology.

[30]  P. Heiduschka,et al.  Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. , 2007, American journal of ophthalmology.

[31]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[32]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[33]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.

[34]  P. Campochiaro,et al.  Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. , 2015, American journal of ophthalmology.

[35]  Glenn J Jaffe,et al.  Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.

[36]  Glenn J Jaffe,et al.  Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. , 2014, Ophthalmology.

[37]  P. Campochiaro,et al.  Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. , 2014, Ophthalmology.

[38]  P. Campochiaro,et al.  Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. , 2011, Ophthalmology.

[39]  Mark Michels,et al.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.